MoonLake Immunotherapeutics financial data

Symbol
MLTX on Nasdaq
Location
Dorfstrasse 29, Zug, Switzerland
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.51K % -63.4%
Debt-to-equity 23.3 % +665%
Return On Equity -55.6 % -260%
Return On Assets -45.2 % -201%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 1.14B USD +1.79%
Weighted Average Number of Shares Outstanding, Basic 63.4M shares +0.75%
Weighted Average Number of Shares Outstanding, Diluted 63.4M shares +0.75%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 187M USD +133%
General and Administrative Expense 42M USD +49.8%
Operating Income (Loss) -229M USD -111%
Income Tax Expense (Benefit) 404K USD +41.7%
Net Income (Loss) Attributable to Parent -210M USD -161%
Earnings Per Share, Basic -3 USD/shares -163%
Earnings Per Share, Diluted -3 USD/shares -163%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 351M USD -6.63%
Assets, Current 411M USD -19.7%
Property, Plant and Equipment, Net 622K USD +6.99%
Operating Lease, Right-of-Use Asset 1.91M USD -41.2%
Other Assets, Noncurrent 587K USD
Assets 414M USD -20%
Employee-related Liabilities, Current 4.2M USD +43.7%
Liabilities, Current 48.4M USD +141%
Operating Lease, Liability, Noncurrent 486K USD -74.9%
Liabilities 123M USD +442%
Accumulated Other Comprehensive Income (Loss), Net of Tax 278K USD -90.2%
Retained Earnings (Accumulated Deficit) -400M USD -111%
Stockholders' Equity Attributable to Parent 289M USD -40.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 291M USD -41.2%
Liabilities and Equity 414M USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -38.1M USD -155%
Net Cash Provided by (Used in) Financing Activities 73.1M USD +43.4%
Net Cash Provided by (Used in) Investing Activities 56.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 91.1M USD +1153%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 351M USD -6.63%
Deferred Tax Assets, Valuation Allowance 24.9M USD +121%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure 0%
Deferred Tax Assets, Gross 25M USD +121%
Operating Lease, Liability 1.99M USD -41.3%
Depreciation 22.8K USD +593%
Payments to Acquire Property, Plant, and Equipment 35K USD -83.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -213M USD -162%
Lessee, Operating Lease, Liability, to be Paid 2.06M USD -42.3%
Operating Lease, Liability, Current 1.5M USD +3.75%
Lessee, Operating Lease, Liability, to be Paid, Year Two 147K USD -88.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.27M USD -19.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 79K USD -59.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 147K USD +4.77%
Deferred Tax Assets, Operating Loss Carryforwards 20.4M USD +203%
Lessee, Operating Lease, Liability, to be Paid, Year Four 100K USD -28.7%
Operating Lease, Payments 368K USD +1.1%
Additional Paid in Capital 689M USD +2.04%
Depreciation, Depletion and Amortization 378K USD +15.2%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 11.2M USD +61.7%